---
schema_version: "secwatch.filing_event.v1"
accession: "0001108205-24-000047"
form_type: "8-K"
ticker: "CRIS"
cik: "0001108205"
company_name: "CURIS INC"
filed_at: "2024-05-23T23:59:59+00:00"
generated_at: "2026-06-01T09:03:11.122213+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Curis cuts workforce ~30%, focuses on combo studies; cash runway into 2025

## Summary
- Board approved ~30% workforce reduction as monotherapy trials near completion.
- Company focusing on combination studies in CNS lymphoma and front-line AML.
- Expects no significant 2024 cost impact; cost reductions anticipated in 2025.
- Stockholders approved increasing authorized common shares to 34,171,875.
- Stockholders approved additional 942,100 shares for 2010 Stock Incentive Plan.

## SEC filing metadata
- accession: 0001108205-24-000047
- form_type: 8-K
- ticker: CRIS
- cik: 0001108205
- company_name: CURIS INC
- filed_at: 2024-05-23T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.03, 5.03, 5.02, 5.07, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1108205/000110820524000047/0001108205-24-000047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1108205/000110820524000047/cris-20240521.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001108205-24-000047
- JSON: https://secwatch.observer/filing/0001108205-24-000047.json
- Plain text: https://secwatch.observer/filing/0001108205-24-000047.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.